🏛️ Verified NIH Record • Updated 2025-09-12
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (NCT03485378)
Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (ASPIRE-ILD): A Phase II Trial
🔵 Active, Not Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.
Who can join: Review the eligibility criteria below.
Location: Alberta Health Services, Cross Cancer Institude — Edmonton, Alberta
Age range: 18 Years
🧪 Interventions in This Study
- Stereotactic Ablative Radiotherapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Alberta Health Services, Cross Cancer Institude — Edmonton, Alberta
- London Regional Cancer Program of the Lawson Health Research Institute — London, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- UHN Princess Margaret Cancer Centre — Toronto, Ontario
- CHUM Université de Montréal — Montreal, Quebec
- Edinburgh Cancer Centre, Western General Hospital — Edinburgh,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Small Cell Lung Cancer
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas
Explore by condition: All Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.